Bronchodilating β-agonist compositions and methods
원문보기
IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
UP-0688463
(2007-03-20)
|
등록번호 |
US-7541385
(2009-07-01)
|
발명자
/ 주소 |
- Chaudry, Imtiaz A.
- Pham, Stephen
- Banerjee, Partha S.
|
인용정보 |
피인용 횟수 :
6 인용 특허 :
51 |
초록
▼
Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of broncho
Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
대표청구항
▼
What is claimed is: 1. A method of treating undesired and/or uncontrolled bronchoconstriction comprising the steps of: (a) adding to a nebulizer, from a propellant-free, sterile unit dose package about 0.1 to about 3.0 mL of a pharmaceutical composition comprising (R) formoterol or a salt thereof a
What is claimed is: 1. A method of treating undesired and/or uncontrolled bronchoconstriction comprising the steps of: (a) adding to a nebulizer, from a propellant-free, sterile unit dose package about 0.1 to about 3.0 mL of a pharmaceutical composition comprising (R) formoterol or a salt thereof at a concentration of from about 0.08 μg/mL to about 43 μg/mL based on formoterol free base, in a pharmacologically suitable solution, wherein the composition further comprises water and a buffer having a concentration of from about 1 mM to about 50 mM, said composition having a pH of about 4.0 to about 6.0, and having an estimated shelf life of greater than 90% after 3 months storage at 25° C. and after 3 years storage at 5° C. (b) directly administering said composition to a subject in need thereof, without dilution or other modification of said prior to administration. 2. A method of treating undesired and/or uncontrolled bronchoconstriction comprising the steps of: (a) adding to a nebulizer from a propellant-free, sterile unit dose package about 0.1 to about 3.0 mL of a pharmaceutical composition comprising (R) formoterol or a salt thereof at a concentration of from about 0.08 μg/mL to about 43 μg/mL based on formoterol free base, in a pharmacologically suitable solution, wherein the composition further comprises water and a buffer having a concentration of from about 1 mM to about 50 mM, said composition having a pH of about 4.0 to about 6.0, and having an estimated shelf life of greater than about 94% after 3 months storage at 25° C. and greater than about 96% after 3 months storage at 5° C.; and (b) directly administering said composition to a subject in need thereof, without dilution or other modification of said prior to administration. 3. A method of treating undesired and/or uncontrolled bronchoconstriction comprising the steps of: (a) adding from a propellant-free, sterile unit dose package to a nebulizer about 0.1 to about 3.0 mL of a pharmaceutical composition comprising (R) formoterol or a salt thereof at a concentration of from about 0.08 μg/mL to about 43 μg/mL based on formoterol free base, in a pharmacologically suitable solution, wherein the composition further comprises water and a citrate buffer at a concentration of from about 1 mM to about 20 mM, said composition having a pH of about 4.5 to about 5.5; and (b) directly administering said composition to a subject in need thereof, without dilution or other modification of said composition prior to administration. 4. The method of treating undesired and/or uncontrolled bronchoconstriction as in any one of claims 1, 2 and 3 wherein said undesired and/or uncontrolled bronchoconstriction is a symptom or condition of asthma. 5. The method of treating undesired and/or uncontrolled bronchoconstriction as in any one of claims 1, 2 and 3 wherein said undesired and/or uncontrolled bronchoconstriction is a symptom or condition of chronic obstructive pulmonary disease. 6. The method of treating undesired and/or uncontrolled bronchoconstriction as in any one of claims 1, 2 and 3 wherein said buffer is present at a concentration of between about 1 mM and about 50 mM. 7. The method of treating undesired and/or uncontrolled bronchoconstriction as in any one of claims 1 and 2 wherein said buffer is present at a concentration of between about 1 mM and about 20 mM. 8. The method of treating undesired and/or uncontrolled bronchoconstriction as in any one of claims 1, 2 and 3 wherein said composition has a pH of about 5. 9. The method of treating undesired and/or uncontrolled bronchoconstriction of claim 8 wherein said buffer has a pH of about 5. 10. The method of treating undesired and/or uncontrolled bronchoconstriction as in any one of claims 1 and 2, wherein about 2.0 mL of the composition is nebulized. 11. The method of treating undesired and/or uncontrolled bronchoconstriction as in any of claims 1, 2 or 3, wherein said (R) formoterol or a salt thereof is (R) formoterol tartrate.
이 특허에 인용된 특허 (51)
-
Jerussi Thomas P. ; Senanayake Chris Hugh, (S,R) formoterol methods and compositions.
-
Murakami Masuo (Tokyo JA) Takahashi Kozo (Tokyo JA) Mase Toshiyasu (Tokyo JA) Murase Kiyoshi (Urawa JA) Ida Hisashi (Urawa JA),
a
상세보기
※ AI-Helper는 부적절한 답변을 할 수 있습니다.